However, during this process, exosomal ANXA2 derived from ovarian cancer cells has no significant effect on the proliferation of HMrSV5 cells, which may act in the early stage of ovarian cancer intraperitoneal implantation, and the proliferation capacity is not sufficient to change, or the process was affected and regulated by other proteins and nucleic acids which warrants further investigation. Here, ANXA2 is linked to ovarian cancer.